IRIS

1,3-Butadiene

CASRN 106-99-0 | DTXSID3020203

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (27 pp, 187 K) Last Updated: 11/05/2002
Information reviewed but value not estimated.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (27 pp, 187 K) Last Updated: 11/05/2002

System RfC (mg/m3) Basis PoD Composite UF Confidence
Reproductive 2 x 10-3 Ovarian atrophy BMCL10 (HEC): 1.98
mg/m3
1000 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (27 pp, 187 K) Last Updated: 11/05/2002

WOE Characterization Framework for WOE Characterization
Carcinogenic to humans Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999)
Basis:
  • Under EPA's 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 1,3-butadiene is characterized as carcinogenic to humans by inhalation. This characterization is supported by the total weight of evidence provided by the following: (1) sufficient evidence from epidemiologic studies of the majority of U.S. workers occupationally exposed to 1,3-butadiene, either to the monomer or to the polymer by inhalation, showing increased lymphohematopoietic cancers and a dose-response relationship for leukemias in polymer workers (see Section II.A.2), (2) sufficient evidence in laboratory animal studies showing that 1,3-butadiene causes tumors at multiple sites in mice and rats by inhalation (see Section II.A.3), and (3) numerous studies consistently demonstrating that 1,3-butadiene is metabolized into genotoxic metabolites by experimental animals and humans (see Section II.A.4). The specific mechanisms of 1,3-butadiene-induced carcinogenesis are unknown however, the scientific evidence strongly suggests that the carcinogenic effects are mediated by genotoxic metabolites of 1,3-butadiene, i.e., the monoepoxide, the diepoxide, and the epoxydiol.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (27 pp, 187 K)

Information reviewed but value not estimated.


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (27 pp, 187 K)

Inhalation Unit Risk: 3 x 10 -5 per µg/m3
Extrapolation Method: Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.
Tumor site(s): Hematologic
Tumor type(s): Leukemia (Health Canada, 1998; U.S. EPA, 2002)


Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.